Comparative Pharmacology
Head-to-head clinical analysis: FEMLYV versus GILDESS FE 1 5 30.
Head-to-head clinical analysis: FEMLYV versus GILDESS FE 1 5 30.
FEMLYV vs GILDESS FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropins, inhibits ovulation, alters cervical mucus and endometrium.
Combination oral contraceptive: ethinyl estradiol (estrogen) and levonorgestrel (progestin) suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
FEMLYV (norethindrone acetate/ethinyl estradiol) is administered as one tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets. The dosing regimen is continuous cyclic.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours, supporting once-daily dosing in most patients.
Ethinyl estradiol: terminal elimination half-life approximately 13-27 hours (mean ~17 hours); clinical context: supports daily dosing with steady state achieved in ~1 week. Gestodene: terminal elimination half-life approximately 12-15 hours; clinical context: allows for maintaining stable serum concentrations with once-daily dosing.
Primarily renal (approximately 60-70% as metabolites, less than 10% as unchanged drug); fecal excretion accounts for about 20-30%.
Ethinyl estradiol (EE) is primarily excreted in urine (40-45%) and feces (40-45%) as glucuronide and sulfate conjugates; less than 8% is excreted unchanged. Gestodene is extensively metabolized; its metabolites are excreted in urine (50-60%) and feces (30-40%), with less than 1% unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive